Verastem, Inc. (VSTM) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Verastem, Inc. is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its primary commercial product is AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib), approved by the FDA in May 2025 for recurrent low-grade serous ovarian cancer (LGSOC). The company is also advancing its pipeline, notably the KRAS G12D inhibitor VS-7375.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $40.1 million | $58.7 million | $2.1 million | $2.1 million |
| Product Revenue (Net) | $25.1 million | $43.7 million | $2.1 million | $2.1 million |
| Net Loss | $(34.7) million | $(71.3) million | $(25.9) million | $(78.0) million |
| Net Loss Per Share (Diluted) | $(0.35) | $(0.81) | $(0.62) | $(1.41) |
| Cash & Equivalents | $136.4 million (as of June 30, 2026) | |||
| Long-Term Debt | $73.8 million (Fair Value) | |||
| Operating Cash Flow | $(96.0) million (YTD) | $(71.3) million (YTD) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 1,775% quarter-over-quarter and 2,649% year-over-year. This was driven by a $15.0 million milestone payment from Secura Bio (triggered by COPIKTRA sales exceeding $200 million) and a 1,074% increase in product revenue from AVMAPKI FAKZYNJA CO-PACK.
- Expense Growth: Operating expenses rose 59% QoQ and 51% YoY. Research and Development (R&D) expenses increased 67% QoQ, primarily due to the initiation of Phase 2 trials for VS-7375 (TARGET-D program) and increased CRO/investigator fees.
- Debt & Warrants: The company recorded a $9.3 million gain from the change in fair value of warrant liability in the first half of 2026 as all outstanding warrants were exercised or expired. The company holds $75.0 million in principal notes under a Note Purchase Agreement.
- Going Concern: Management has disclosed substantial doubt about the company's ability to continue as a going concern for the next 12 months due to increased projected R&D costs for the VS-7375 program, despite existing cash resources.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- VS-7375: Received FDA Fast Track Designation for NSCLC. Phase 2 trials (TARGET-D 201, 202, 203) are ongoing with enrollment expected to complete by end of 2026. Phase 3 pivotal trials are expected to begin in H1 2027.
- AVMAPKI FAKZYNJA: Phase 3 RAMP 301 trial is fully enrolled; topline data expected mid-2027.
- Financing: The company expects to fund operations through existing cash, product revenue, and potential future milestones. A subsequent event (August 2026) amended the Note Purchase Agreement to allow for new "Revenue Notes" tied to sales performance.
- Risks:
- Liquidity: Substantial doubt regarding going concern status if additional capital cannot be raised or revenue targets are not met.
- Regulatory: Uncertainty regarding approval of new indications and product candidates.
- Concentration: Two customers accounted for over 65% of trade accounts receivable and significant portions of product revenue.
Investor Verification Checklist
- Going Concern Assessment: Verify the company's specific plan to secure additional financing given the explicit "substantial doubt" disclosure.
- Revenue Sustainability: Distinguish between the one-time $15.0 million Secura milestone and recurring product revenue growth rates for AVMAPKI FAKZYNJA.
- VS-7375 Burn Rate: Review the specific cost drivers for the 67% increase in R&D expenses and the timeline for Phase 2 data readouts (expected October 2026).
- Debt Covenants: Review the terms of the Note Purchase Agreement, specifically the revenue participation percentage (1.00%) and the new "Revenue Notes" structure announced in August 2026.
- Customer Concentration: Assess the risk associated with reliance on two major customers for the majority of product revenue.